Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.

<h4>Introduction</h4>The rapid clearance of factor IX necessitates frequent intravenous administrations to achieve effective prophylaxis for patients with hemophilia B. Subcutaneous administration has historically been limited by low bioavailability and potency. Dalcinonacog alfa was developed using...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Timothy C Nichols, Howard Levy, Elizabeth P Merricks, Robin A Raymer, Martin L Lee
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2020-01-01
coleção:	PLoS ONE
Acesso em linha:	https://doi.org/10.1371/journal.pone.0240896
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!